About OncoGenex

test

News & Events

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

Tuesday, May 28 2013

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer

Thursday, May 23 2013

OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chem

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

Wednesday, May 22 2013

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

Wednesday, May 22 2013

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013

Thursday, May 2 2013

OncoGenex Pharmaceuticals, Inc.

OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

Wednesday, May 1 2013

OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with AB

OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

Tuesday, Apr 30 2013

OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is

Pages

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue